ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Lidocaine (topical): Drug information

Lidocaine (topical): Drug information
(For additional information see "Lidocaine (topical): Patient drug information" and see "Lidocaine (topical): Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
ALERT: US Boxed Warning
Life-threatening and fatal events in infants and young children:

Postmarketing cases of seizures, cardiopulmonary arrest, and death in patients under the age of 3 years have been reported with use of lidocaine 2% viscous solution when it was not administered in strict adherence to the dosing and administration recommendations. In the setting of teething pain, lidocaine 2% viscous solution should generally not be used. For other conditions, the use of the product in patients less than 3 years should be limited to those situations where safer alternatives are not available or have been tried but failed.

To decrease the risk of serious adverse events with use of lidocaine 2% viscous solution, instruct caregivers to strictly adhere to the prescribed dose and frequency of administration and store the prescription bottle safely out of reach of children.

Brand Names: US
  • 7T Lido;
  • Alocane Emergency Burn Max Str [OTC];
  • AneCream [OTC];
  • AneCream5 [OTC];
  • Asperflex Lidocaine [OTC];
  • Asperflex Max St [OTC];
  • Asperflex Pain Relieving [OTC];
  • Astero;
  • Blue Tube/ Aloe [OTC] [DSC];
  • DermacinRx Lidogel;
  • Eha;
  • First Care Pain Relief [OTC];
  • Gen7T;
  • Glydo;
  • GoodSense Burn Relief [OTC];
  • HealthWise Pain Relief [OTC];
  • LDO Plus;
  • LevigoSP [OTC];
  • Lido King [OTC];
  • Lido-Sorb;
  • Lidocaine Max St 24 Hours [OTC];
  • Lidocaine Pain Relief Max St [OTC];
  • Lidocaine Pain Relief [OTC];
  • Lidocaine Plus [OTC];
  • Lidocan;
  • Lidocan II [DSC];
  • Lidocan III;
  • Lidocanna [OTC];
  • Lidocore [OTC];
  • Lidoderm;
  • LidoDose Pediatric Bulk Pack [OTC];
  • LidoDose [OTC];
  • LidoFore Flexipatch [OTC] [DSC];
  • Lidogel [OTC] [DSC];
  • LidoHeal-90 [OTC] [DSC];
  • LidoLite;
  • Lidopac [DSC];
  • Lidopin;
  • LidoPure Patch;
  • Lidorex;
  • LidoRx;
  • Lidosol;
  • Lidosol-50;
  • Lidotral;
  • Lidotran;
  • Lidotrex (Aloe Vera) [DSC];
  • Lidovex [DSC];
  • Lidovix L;
  • Lidozion [DSC];
  • Lipocaine 5 [OTC];
  • LMX 4 Plus [OTC];
  • LMX 4 [OTC];
  • LMX 5 [OTC];
  • Lubricaine [OTC];
  • Lydexa;
  • Medi-First Burn Spray [OTC];
  • Moxicaine [DSC];
  • NeuroMed7 [OTC] [DSC];
  • NumbCream [OTC];
  • Pain Relief Maximum Strength [OTC];
  • Pain Relieving [OTC] [DSC];
  • Pharmacist Choice Pain Relief [OTC];
  • Predator [OTC] [DSC];
  • Premium Lidocaine;
  • Proxivol;
  • RadiaGuard Advanced [OTC];
  • Re-Lieved Maximum Strength [OTC];
  • RectaSmoothe [OTC];
  • RectiCare [OTC];
  • RectoProtect [OTC];
  • Salonpas Pain Relieving [OTC];
  • Sun Burnt Plus [OTC];
  • TheraCare Pain Relief [OTC];
  • Topicaine 5 [OTC];
  • Topicaine [OTC];
  • Venipuncture Px1 Phlebotomy;
  • XeroBurn [OTC];
  • Xolido XP [OTC] [DSC];
  • Xolido [OTC] [DSC];
  • Xyliderm;
  • ZiloVal [DSC];
  • Zingo;
  • Zionodil;
  • Zionodil 100;
  • ZTlido;
  • Zylotrol-L [OTC] [DSC]
Brand Names: Canada
  • Cathejell;
  • Jelido;
  • Lidodan;
  • Lidodan Endotracheal;
  • Xylocaine;
  • Xylocaine Spray
Pharmacologic Category
  • Analgesic, Topical;
  • Local Anesthetic
Dosing: Adult
Anesthesia, topical

Anesthesia, topical: Note: Not all available products may be represented in dosing; also refer to manufacturer's labeling.

Cream:

Aspercreme: Pain: Apply a thin layer to affected area every 6 to 8 hours, not to exceed 3 applications in a 24-hour period.

Blue Tube, LMX 4: Skin irritation: Apply up to 3 to 4 times daily to intact skin.

Lidotran 3.88%, Lidocaine 4.12%, Lidovex 3.75%: Skin irritation: Apply a thin film to affected area 2 to 3 times daily as needed.

Lipocaine 5, LMX 5: Relief of anorectal pain and itching: Apply to affected area up to 6 times daily.

Gel: Usual dosage: Apply to affected area ≤4 times daily as needed (maximum dose: 4.5 mg/kg, not to exceed 300 mg).

Product-specific dosing:

Astero 4%; Apply 1 to 4 pumps to affected area; each pump provides 0.25 mL (lidocaine 10 mg) and covers a 2 × 2 inch area. Maximum single application: 4 pumps (lidocaine 40 mg); maximum daily application: 12 pumps/day (lidocaine 120 mg/day).

LidoRx 3%: Apply 1 to 4 pumps to affected area 3 to 4 times daily; each pump provides 0.25 mL (lidocaine 7.5 mg) and covers a 2 × 2 inch area. Maximum single application: 4 pumps (lidocaine 30 mg); maximum daily application: 16 pumps/day (lidocaine 120 mg/day).

Topicaine 5%: Apply to affected area up to 6 times daily.

Intradermal injection: Apply one intradermal lidocaine (0.5 mg) device to the site planned for venipuncture, 1 to 3 minutes prior to needle insertion.

Jelly: Maximum dose: 30 mL (600 mg) in any 12-hour period:

Anesthesia of male urethra: 5 to 30 mL (100 to 600 mg).

Anesthesia of female urethra: 3 to 5 mL (60 to 100 mg).

Lubricant, endotracheal intubation (Glydo): Apply moderate amount to external surface of the endotracheal tube prior to insertion.

Lotion: Apply a thin film to affected area 2 to 4 times daily; product-specific application frequency may vary; also refer to manufacturer's labeling.

Ointment:

Intubation (5% ointment only): Apply 5 g of ointment (equivalent to lidocaine base 250 mg [~6 inches of ointment]) in a single application to the tube prior to intubation; maximum: 20 g of ointment/day (equivalent to lidocaine base 1,000 mg/day).

Pain (eg, skin irritation, sunburn): Apply to affected area 3 to 4 times daily, not to exceed 5 g of ointment (equivalent to lidocaine base 250 mg) in a single application; maximum: 20 g of ointment/day (equivalent to lidocaine base 1,000 mg/day).

Oral topical solution (2% viscous):

Anesthesia of the mouth: 15 mL swished in the mouth and spit out no more frequently than every 3 hours (maximum: 4.5 mg/kg [or 300 mg per dose]; 8 doses per 24-hour period).

Anesthesia of the pharynx: 15 mL gargled no more frequently than every 3 hours (maximum: 4.5 mg/kg [or 300 mg per dose]; 8 doses per 24-hour period); may be swallowed.

Oral topical solution (4%): Note: For use in mucous membranes of oral and nasal cavities and proximal GI tract. Apply 1 to 5 mL (40 to 200 mg) to affected area (maximum dose: 4.5 mg/kg, not to exceed 300 mg per dose).

Oral topical endotracheal solution, metered-dose spray (10 mg/actuation) [Canadian product]:

Nasal: 20 to 60 mg (maximum dose: 500 mg for procedure <1 minute or 600 mg for procedure >5 minutes).

Oropharyngeal: 20 to 200 mg (maximum dose: 500 mg for procedure <1 minute or 600 mg for procedure >5 minutes).

Respiratory tract: 50 to 400 mg (maximum dose: 400 mg for procedure <1 minute or 600 mg for procedure >5 minutes).

Trachea, larynx, bronchi: 50 to 200 mg (maximum dose: 200 mg for procedure <1 minute or 400 mg for procedure >5 minutes).

Patch:

Pain (localized):

3.5% products: Apply patch to painful area. Patch may remain in place for up to 12 hours in any 24-hour period. No more than 1 patch should be used in a 24-hour period.

4% products: Apply patch to painful area. Note: The manufacturer’s recommendations for the number of patches that can be applied within a 24-hour period varies from 1 to 4 times daily and the duration of application varies from 8 to 24 hours; refer to the manufacturer’s labeling for product-specific recommendations.

Postherpetic neuralgia (1.8% [ZTlido], 5% products): Note: One ZTlido 1.8% patch provides equivalent lidocaine exposure to one 5% patch: Apply patch to most painful area. Up to 3 patches may be applied in a single application. Patch(es) may remain in place for up to 12 hours in any 24-hour period.

Rectal suppository: Note: Lidocaine suppositories have been discontinued in the United States for >1 year. Insert 1 suppository (50 mg) rectally; maximum of 4 suppositories in 24 hours.

Topical solution (OTC 4% [products labeled for external use only]): Apply thin layer to affected area every 6 to 8 hours; maximum of 3 applications in 24 hours.

Topical spray (OTC 4% [products labeled for external use only]): Apply to affected area up to 3 to 4 times daily; maximum of 4 applications in 24 hours.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling; use caution in patients with severe hepatic disease.

Dosing: Older Adult

Refer to adult dosing. Administer reduced doses commensurate with age and physical status.

Dosing: Pediatric

(For additional information see "Lidocaine (topical): Pediatric drug information")

Dosage guidance:

Dosing: Smaller areas of treatment are recommended in younger or smaller patients (<12 months or <10 kg) or those with impaired elimination (Ref); use lowest effective dose.

Anesthetic

Anesthetic: Topical: Dose varies with age, weight, and physical condition.

Cream:

Lidovex (lidocaine 3.75%), Lidocaine 4.12%: Infants, Children, and Adolescents: Apply a thin film to affected area 2 to 3 times daily as needed; maximum dose: 4.5 mg/kg/dose; not to exceed 300 mg/dose

LMX 4 (lidocaine 4%): Children >2 years and Adolescents: Apply a thin film to affected area up to 3 to 4 times daily as needed; maximum dose: 4.5 mg/kg/dose; not to exceed 300 mg/dose

Gel: Children ≥2 years and Adolescents: Apply to affected area up to 3 to 4 times daily as needed; maximum dose: 4.5 mg/kg/dose; not to exceed 300 mg/dose

Jelly: Children and Adolescents: Dose varies with age and weight; maximum dose: 4.5 mg/kg/dose; not to exceed 600 mg in a 12-hour period

Lotion: Children and Adolescents: Apply to affected area up to 2 to 3 times daily as needed; maximum dose: 4.5 mg/kg/dose; not to exceed 300 mg/dose

Ointment: Children and Adolescents: Apply to affected area; maximum dose: 4.5 mg/kg/dose; not to exceed 300 mg/dose

Patch: OTC 4%: Children ≥12 years and Adolescents: Apply patch to painful area. Patch may remain in place for up to 12 hours. No more than 1 patch should be used in a 24-hour period.

Minor dermal procedures; anesthetic

Minor dermal procedures (eg, peripheral IV cannulation, venipuncture, lumbar puncture, abscess drainage, joint aspiration); anesthetic: Limited data available:

Intradermal injection: Zingo: Venipuncture or peripheral IV catheter insertion: Children ≥3 years and Adolescents: Apply one intradermal lidocaine (0.5 mg) device to the site planned for venipuncture, administer 1 to 3 minutes prior to the IV needle insertion; perform procedure within 10 minutes of application

Topical: Cream LMX 4 (lidocaine 4%):

Infants and Children <4 years: Apply 1 g of cream to site 30 minutes prior to procedure (Ref)

Children ≥4 years and Adolescents ≤17 years: Apply 1 to 2.5 g of cream to site 30 minutes prior to procedure (Ref)

Note: For peripheral IV cannulation, some have recommended application to 6.25 cm2 of skin (Ref).

Oral inflammation or irritation

Oral inflammation or irritation: Topical: Note: Not approved for relief of teething pain and discomfort in infants and children; serious adverse (toxic) effects, including fatalities, have been reported; AAP, AAPD, and ISMP strongly discourage use (Ref).

Oral solution (2% viscous): Dose should be adjusted according to patient's age, weight, and physical condition:

Infants and Children <3 years: 24 mg/dose (1.2 mL) applied to area with a cotton-tipped applicator no more frequently than every 3 hours; maximum dose: 4 doses per 12-hour period; should not be swallowed

Children ≥3 years and Adolescents: Do not exceed 4.5 mg/kg/dose; maximum dose: 300 mg/dose; swished in the mouth and spit out no more frequently than every 3 hours; maximum dose: 4 doses per 12-hour period

Topical solution (4%): Note: For use on mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract; use lowest effective dose. Children and Adolescents: Do not exceed 4.5 mg/kg/dose; maximum dose: 300 mg/dose; applied with cotton applicator, cotton pack, or via spray; should not be swallowed

Topical endotracheal solution, metered-dose spray (10 mg/actuation) [Canadian product]: Children 2 to <12 years: Topical: Dose varies with age, weight, and application site.

Maximum dose:

Laryngotracheal: 3 mg/kg/dose

Nasal/oropharyngeal: 4 to 5 mg/kg/dose

Rectal pain, itching

Rectal pain, itching: Topical:

Cream: LMX 5 (lidocaine 5%): Children ≥12 years and Adolescents: Apply to affected area up to 6 times daily

Gel: Topicaine (lidocaine 5%): Children ≥12 years and Adolescents: Apply to affected area up to 6 times daily

Skin irritation

Skin irritation: Topical: Cream: LMX 4 (lidocaine 4%): Children ≥2 years and Adolescents: Apply up to 3 to 4 times daily to intact skin

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling. Use caution in patients with severe renal impairment; accumulation of active metabolites may occur with long-term treatment.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; use caution in patients with severe hepatic disease.

Adverse Reactions (Significant): Considerations
Hypersensitivity reactions

Reports of systemic hypersensitivity reactions following administration of topical lidocaine to mucous membranes, generally in the context of a procedure or nebulized lidocaine where systemic absorption is more likely, are rare (Ref). These reactions may also result from excipients in lidocaine formulations (Ref). Patients allergic to para-aminobenzoic acid (PABA) derivatives (eg, procaine, tetracaine, benzocaine) have not shown cross sensitivity to lidocaine.

Contact dermatitis, a localized delayed Type IV hypersensitivity reaction, has also been reported with the use of lidocaine applied to the skin (Ref). These reactions may also result from excipients in lidocaine formulations (Ref). Type I hypersensitivity reactions are not of concern solely based on the presence of allergic contact dermatitis (Ref). Systemic toxicity has also been reported rarely with topical application (Ref).

Mechanism: Non–dose-related; immunologic. Signs and symptoms of immediate hypersensitivity reactions (eg, anaphylaxis) may be mediated by IgE or non-IgE mechanisms (ie, direct stimulation of mast cell and/or basophils, complement activation) (Ref). Allergic contact dermatitis is a delayed, T-lymphocyte–mediated reaction (Ref).

Onset: Immediate hypersensitivity reactions: Rapid; usually occurs within 1 hour of administration; but may occur up to 6 hours after exposure (Ref). Allergic contact dermatitis generally occurs within 48 hours after application (Ref).

Risk factors:

• Cross-reactivity with other amide anesthetics, including bupivacaine, mepivacaine, and prilocaine, has been reported (Ref).

Local anesthetic systemic toxicity

Topical lidocaine administration to mucous membranes, generally in the context of a procedure or nebulized lidocaine where systemic absorption is more likely, is associated with infrequent but potentially life-threatening local anesthetic systemic toxicity (LAST), a syndrome of CNS excitation and/or depression followed by cardiotoxicity, in some cases (Ref). CNS effects include blurred vision, confusion, dizziness, drowsiness, respiratory depression, seizures, tremors, coma, and respiratory arrest (Ref). Drowsiness may be an early sign of high lidocaine serum concentrations (Ref). Cardiovascular effects include bradycardia, hypotension, cardiovascular collapse, and cardiac arrest (Ref). CNS effects typically precede cardiotoxicity. Symptom severity increases with increasing lidocaine serum concentrations (Ref). Symptoms of LAST may be reversible with prompt treatment (Ref).

Mechanism: Dose-related (Ref); blockage of voltage-gated sodium channels in the CNS disrupts depolarization of inhibitory neurons, leading to neural excitation (Ref). With increasing lidocaine plasma concentrations, CNS depression occurs. Sodium channel blockade in myocardial tissue results in action potential inhibition, decreased contractility, conduction disturbance, and/or arrhythmia (Ref).

Onset: Rapid; typically occurs within minutes of exposure (Ref). Severe symptoms may appear within hours of initial symptoms (Ref).

Risk factors:

• Lidocaine blood concentration >5 mcg/mL

• Application to mucous membranes in high doses (preceding airway instrumentation for awake intubation) (Ref)

• Intentional or unintentional overdose (Ref)

• Extremes of ages (<16 or >60 years of age) (Ref)

• Low muscle mass (neonates, infants, debilitated older patients) (Ref)

• Females (Ref)

• Pregnancy (Ref)

• Chronic malnutrition (Ref)

• Organ dysfunction (eg, cardiac, CNS, hepatic, kidney) (Ref)

• Acidosis (Ref)

• Hypoxia (Ref)

Methemoglobinemia

Topical lidocaine administration to mucous membranes, generally in the context of a procedure or nebulized lidocaine where systemic absorption is more likely, is rarely associated with methemoglobinemia, a serious and possibly life-threatening condition that is reversible with prompt treatment. Symptoms of methemoglobinemia include cyanosis (pale, gray, or blue skin), headache, fatigue, shortness of breath, and tachycardia. Severity of symptoms varies based on the level of methemoglobin in the blood (Ref).

Mechanism: Non–dose-related; idiosyncratic. Topical lidocaine exposure via mucous membrane(s) leads to acceleration of heme iron oxidation and conversion from the ferrous to ferric state, producing methemoglobin (Ref). Blood methemoglobin levels increase above the compensatory ability of the body, resulting in clinically significant methemoglobinemia (Ref). Because methemoglobin transports and releases less oxygen into peripheral tissues than normal hemoglobin, hypoxia ensues.

Onset: Rapid; typically occurs within minutes to hours of exposure (Ref)

Risk factors:

• Glucose-6-phosphate dehydrogenase (G6PD) deficiency

• Congenital or idiopathic methemoglobinemia

• Cardiac or pulmonary compromise (acute and/or chronic)

• Age <6 months

• Concurrent exposure to oxidizing agents or their metabolites (eg, dapsone, nitroglycerin, sulfamethoxazole) (Ref)

• Concurrent exposure to other local anesthetics (eg, benzocaine, prilocaine)

Adverse Reactions

The following adverse drug reactions are derived from product labeling unless otherwise specified. Adverse effects may vary with formulation and extent of systemic absorption; children may be at increased risk.

Frequency not defined:

Cardiovascular: Bradycardia, circulatory shock, flushing, hypotension, shock

Dermatologic: Exfoliation of skin, papule of skin, skin blister, skin depigmentation, skin erosion, urticaria

Gastrointestinal: Dysgeusia, metallic taste, nausea, vomiting

Hematologic & oncologic: Bruise

Hypersensitivity: Angioedema, hypersensitivity reaction, nonimmune anaphylaxis

Local: Application-site burning, application-site dermatitis, application-site edema, application-site erythema, application-site irritation, application-site pruritus, application-site purpuric or petechial reaction, application-site scaling, application-site vesicles, local skin discoloration, localized warm feeling

Nervous system: Apprehension, asthenia, central nervous system depression, confusion, disorientation, dizziness, drowsiness, euphoria, excitement, headache, hyperesthesia, hypoesthesia, loss of consciousness, nervousness, numbness, paresthesia, seizure, sensation disorder (including sensation of cold), tremor, twitching

Neuromuscular & skeletal: Laryngospasm

Ophthalmic: Blurred vision, diplopia

Otic: Tinnitus

Respiratory: Bronchospasm, dyspnea, respiratory depression

Postmarketing:

Dermatologic: Contact dermatitis (Montanez-Wiscovich 2018)

Hematologic & oncologic: Methemoglobinemia (Gay 2016)

Contraindications

Hypersensitivity to lidocaine or any component of the formulation; hypersensitivity to another local anesthetic of the amide type; traumatized mucosa, bacterial infection at the site of application (lotion, LidoRx, and Lidovex); tuberculous or fungal lesions of skin vaccinia, varicella and acute herpes simplex (3.88% and 4.12% cream).

Warnings/Precautions

Concerns related to adverse effects:

• Familial malignant hyperthermia: Many drugs used during the conduct of anesthesia may trigger familial malignant hyperthermia; not known whether amide-type local anesthetics trigger this reaction. However, standard protocol for management should be available. Early unexplained signs of tachycardia, tachypnea, labile blood pressure, and metabolic acidosis may precede temperature elevation. If familial malignant hyperthermia is confirmed, discontinue triggering agent and initiate appropriate therapy (eg, oxygen, dantrolene) and other supportive measures.

• Local effects: Irritation, sensitivity and/or infection may occur at the site of application; discontinue use and institute appropriate therapy if local effects occur. Mild and transient application site reactions may occur during or immediately after treatment with patch; spontaneously resolves within a few minutes to hours; may include blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechial, pruritus, vesicles, or the area may be the locus of abnormal sensation.

Disease-related concerns:

• Bleeding tendencies/platelet disorders: Intradermal injection: Use with caution; may have a higher risk of superficial dermal bleeding.

• Cardiovascular disease: Use with caution in patients with severe shock or heart block.

• Dermal integrity reduced: Application to broken or inflamed skin may lead to increased systemic absorption; use caution.

• Hepatic impairment: Use caution in patients with severe hepatic disease due to diminished ability to metabolize systemically-absorbed lidocaine.

• Pseudocholinesterase deficiency: Use with caution; these patients have a greater risk of developing toxic plasma concentrations of lidocaine.

• Sepsis/severely traumatized mucosa: Use with extreme caution in the presence of sepsis and/or severely traumatized mucosa due to an increased risk of rapid systemic absorption at application site.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.

• Intradermal injection: Only use on intact skin and on skin locations where an adequate seal can be maintained. Do not use on body orifices, mucous membranes, around the eyes, or on areas with a compromised skin barrier.

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.

• Topical cream, liquid, lotion, gel, and ointment: Do not leave on large body areas for >2 hours. Not for ophthalmic use. Some products are not recommended for use on mucous membranes; consult specific product labeling.

• Topical oral solution/viscous: When used in mouth or throat, topical anesthesia may impair swallowing and increase aspiration risk. Avoid food for ≥60 minutes following oral or throat application. This is especially important in the pediatric population. Numbness may increase the danger of tongue/buccal biting trauma; ingesting food or chewing gum should be avoided while mouth or throat is anesthetized. Excessive doses or frequent application may result in high plasma levels and serious adverse effects; strictly adhere to dosing instructions. Use measuring devices to measure the correct volume, if applicable, to ensure accuracy of dose.

• Topical patch: Apply only on intact skin. Do not use around or in the eyes. To avoid accidental ingestion by children, store and dispose of products out of the reach of children. Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub).

Special populations:

• Acutely ill patients: Use with caution; acutely ill patients should be given reduced doses commensurate with their age and physical status.

• Elderly and debilitated patients: Use with caution; elderly and debilitated patients should be given reduced doses commensurate with their age and physical status.

• Pediatric: Use with caution; children should be given reduced doses commensurate with their age and physical status.

Other warnings/precautions:

• Self-medication (OTC use): When used for self-medication, discontinue use and notify health care provider if condition worsens, symptoms persist for >7 days, or symptoms clear up but reoccur within a few days.

• Topical application: When topical anesthetics are used prior to cosmetic or medical procedures, the lowest amount of anesthetic necessary for pain relief should be applied. High systemic levels and toxic effects (eg, methemoglobinemia, irregular heartbeats, respiratory depression, seizures, death) have been reported in patients who (without supervision of a trained professional) have applied topical anesthetics in large amounts (or to large areas of the skin), left these products on for prolonged periods of time, or have used wraps/dressings to cover the skin following application.

Warnings: Additional Pediatric Considerations

In infants and children, seizures (some fatal) have been reported following topical lidocaine ingestion at serum concentrations within the therapeutic range of 1 to 5 mcg/mL (Curtis 2009); others have reported toxic effects with excessive doses or frequent application of topical oral lidocaine solution that resulted in high plasma concentrations. Multiple cases of seizures, including fatalities, have occurred in pediatric patients using viscous lidocaine for oral discomfort (eg, teething pain, herpetic gingivostomatitis) (Curtis 2009; Giard 1983; Gonzalez del Rey 1994; Hess 1988; Mofenson 1983; Puczynski 1985; Rothstein 1982; Smith 1992). Lidocaine oral solution is not approved for treatment of teething pain or discomfort; off-label use is strongly discouraged and should be avoided. When used for oral irritation, the solution should not be swallowed, but should be applied topically with a cotton swab to individual lesions or the excess should be expectorated (swish and spit). Toxicology data suggests that in infants and children<6 years, ingestion of as little as 5 mL of lidocaine may result in serious toxicity and emergency care should be sought (Curtis 2009). Additionally, the FDA recommends against using topical OTC medications for teething pain as some products may cause harm; the use of OTC topical anesthetics (eg, benzocaine) for teething pain is also discouraged by AAP, and The American Academy of Pediatric Dentistry (AAP 2011; AAPD 2012). The AAP recommends managing teething pain with a chilled (not frozen) teething ring or gently rubbing/massaging with the caregiver's finger.

Topical patches (both used and unused) may cause toxicities in children; used patches still contain large amounts of lidocaine; store and dispose patches out of the reach of children; efficacy of patches in pediatric patients has not been evaluated due to safety concerns.

Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, >3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).

Product Availability

Lidocaine suppositories have been discontinued in the United States for >1 year.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Aerosol, External:

Alocane Emergency Burn Max Str: 4% (104 mL)

GoodSense Burn Relief: 0.5% (127 g) [contains disodium edta, methylparaben, propylene glycol, propylparaben, trolamine (triethanolamine)]

Cream, External:

AneCream: 4% (5 g, 15 g, 30 g) [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]

AneCream5: 5% (15 g, 30 g) [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]

Asperflex Lidocaine: 4% (5 g, 15 g, 30 g) [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]

Blue Tube/ Aloe: 4% (30 g [DSC]) [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]

Lidotral: 3.88% (85 g) [contains cetearyl alcohol, methylparaben, propylene glycol, propylparaben]

Lidotran: 3.88% (85 g) [contains cetearyl alcohol, methylparaben, propylene glycol, propylparaben]

Lidovex: 3.75% (60 g [DSC]) [contains cetyl alcohol, propylene glycol, trolamine (triethanolamine)]

Lipocaine 5: 5% (30 g, 113 g) [fragrance free, mineral oil free, no artificial color(s), paraben free; contains cetyl alcohol]

LMX 4: 4% (5 g, 15 g, 30 g) [contains benzyl alcohol]

LMX 5: 5% (15 g, 30 g) [contains benzyl alcohol]

NumbCream: 5% (38 g) [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]

RectaSmoothe: 5% (30 g) [contains cetyl alcohol, methylparaben, propylene glycol, propylparaben]

RectiCare: 5% (15 g, 30 g) [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]

RectoProtect: 5% (30 g) [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]

Generic: 4% (5 g, 15 g, 28 g, 28.35 g, 30 g, 120 g); 5% (14.17 g, 15 g, 28.35 g, 30 g)

Cream, External, as hydrochloride:

Lidocaine Plus: 4% (120 g) [contains cetearyl alcohol, propylene glycol, trolamine (triethanolamine)]

Lidopin: 3% (28 g, 85 g); 3.25% (28 g, 85 g) [contains cetyl alcohol, methylparaben, propylparaben]

Lydexa: 4.12% (28.3 g, 85 g) [contains cetyl alcohol, methylparaben, propylene glycol, propylparaben]

NeuroMed7: 4% (63 g [DSC]) [contains propylene glycol, trolamine (triethanolamine)]

Pain Relieving: 4% (15 g [DSC]) [contains cetearyl alcohol, disodium edta]

Predator: 4% (63 g [DSC]) [contains propylene glycol, trolamine (triethanolamine)]

Xolido: 2% (118 mL [DSC]) [contains methylisothiazolinone]

Xolido XP: 4% (118 mL [DSC]) [contains methylisothiazolinone]

Generic: 3% (28.3 g, 28.35 g, 85 g); 4% (30 g [DSC], 120 g); 4.12% (28.3 g, 85 g)

Gel, External:

DermacinRx Lidogel: 2.8% (100 g) [contains methylparaben, propylene glycol, propylparaben]

Lidogel: 2.8% (100 g [DSC]) [contains methylparaben, propylene glycol, propylparaben]

Lidorex: 2.8% (100 g) [contains methylparaben, propylene glycol, propylparaben]

Lubricaine: 4% (113 g); 5% (113 g) [estrogen free, fragrance free, no artificial color(s), no artificial flavor(s), paraben free, soy free, sugar free; contains benzyl alcohol]

Topicaine: 4% (10 g, 30 g, 113 g) [contains benzyl alcohol, disodium edta]

Topicaine 5: 5% (10 g, 30 g, 113 g) [contains benzyl alcohol, disodium edta]

Gel, External, as hydrochloride:

Alocane Emergency Burn Max Str: 4% (75 mL)

Astero: 4% (90 mL)

LDO Plus: 4% (30 mL)

LidoDose: 3% (1 mL) [contains isopropyl alcohol, trolamine (triethanolamine)]

LidoDose Pediatric Bulk Pack: 3% (1 mL) [contains isopropyl alcohol, trolamine (triethanolamine)]

LidoRx: 3% (10 mL, 30 mL, 90 mL) [contains isopropyl alcohol, trolamine (triethanolamine)]

Lidotrex (Aloe Vera): 2% (28.33 g [DSC]) [contains trolamine (triethanolamine)]

Proxivol: 2% (28.33 g) [contains benzethonium chloride, trolamine (triethanolamine)]

Sun Burnt Plus: 4% (118 mL) [dye free, fragrance free, paraben free, phthalate free, sulfate free]

7T Lido: 2% (85 g) [contains trolamine (triethanolamine)]

XeroBurn: 2% (3.5 g) [contains methylparaben, propylene glycol, propylparaben, trolamine (triethanolamine)]

Generic: 2% (5 mL [DSC], 30 mL [DSC])

Jet-injector, Intradermal, as hydrochloride [preservative free]:

Zingo: 0.5 mg (1 ea)

Generic: 0.5 mg (1 ea [DSC])

Kit, External:

AneCream: 4% [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]

LidoHeal-90: 4% [DSC] [contains cetostearyl alcohol, edetate (edta) disodium, methylparaben, propylene glycol, propylparaben]

LidoLite: 5%

Lidopac: 5% [DSC] [contains polyethylene glycol (macrogol)]

LidoPure Patch: 5% [contains edetate (edta) disodium, methylparaben, propylene glycol, propylparaben]

Lidosol: 5%

Lidosol-50: 5% [contains polyethylene glycol (macrogol)]

Lidovix L: 5% [contains polyethylene glycol (macrogol)]

LMX 4 Plus: 4% [contains benzyl alcohol]

Moxicaine: 5% [DSC] [contains polyethylene glycol (macrogol)]

Xyliderm: 5% [contains edetate (edta) disodium, methylparaben, propylene glycol, propylparaben]

ZiloVal: 5% [DSC]

Zylotrol-L: 4% [DSC] [contains polysorbate 80]

Generic: 4%

Kit, External, as hydrochloride:

Venipuncture Px1 Phlebotomy: 2% [latex free; contains methylparaben, propylparaben]

Liquid, External, as hydrochloride:

LevigoSP: 2.5% (150 mL) [paraben free; contains propylene glycol]

Lotion, External:

Gen7T: 3.5% (120 g) [contains edetate (edta) disodium, trolamine (triethanolamine)]

RadiaGuard Advanced: 1% (113 g) [metallic free; contains cetyl alcohol, polysorbate 80, trolamine (triethanolamine)]

Lotion, External, as hydrochloride:

Eha: 4% (88 mL) [contains methylisothiazolinone]

Lido-Sorb: 3% (177 mL) [contains cetyl alcohol, edetate (edta) disodium, methylparaben, propylparaben]

Lidozion: 3% (177 mL [DSC]) [contains cetyl alcohol, edetate (edta) disodium, methylparaben, propylparaben]

Zionodil: 3% (177 mL) [contains cetyl alcohol, edetate (edta) disodium, methylparaben, propylparaben]

Zionodil 100: 3% (177 mL) [contains cetyl alcohol, propylene glycol, trolamine (triethanolamine)]

Generic: 3% (177 mL)

Ointment, External:

Asperflex Lidocaine: 4% (100 g) [contains polysorbate 80]

Premium Lidocaine: 5% (50 g)

Generic: 4% (50 g); 5% (30 g, 35.44 g, 50 g, 2500 g [DSC])

Pad, External:

Alocane Emergency Burn Max Str: 4% (1 ea)

Patch, External:

Asperflex Max St: 4% (6 ea) [odor free]

Asperflex Pain Relieving: 4% (5 ea) [fragrance free; contains polysorbate 80, propylene glycol]

First Care Pain Relief: 4% (5 ea) [odor free, paraben free]

First Care Pain Relief: 4% (5 ea [DSC]) [odor free, paraben free; contains propylene glycol]

Gen7T: 3.5% (10 ea, 15 ea) [contains propylene glycol]

HealthWise Pain Relief: 4% (15 ea) [odor free; contains methylparaben, polysorbate 80, propylene glycol, propylparaben]

Lido King: 4% (5 ea) [contains edetate (edta) disodium, methylparaben, propylene glycol, propylparaben]

Lidocaine Max St 24 Hours: 4% (15 ea) [odor free]

Lidocaine Pain Relief: 4% (5 ea, 30 ea) [contains methylparaben, polysorbate 80, propylene glycol, propylparaben]

Lidocaine Pain Relief Max St: 4% (1 ea, 5 ea) [odorless; contains edetate (edta) disodium, methylparaben, propylene glycol, propylparaben]

Lidocan: 5% (1 ea, 30 ea) [contains disodium edta, methylparaben, propylene glycol, propylparaben]

Lidocan II: 5% (1 ea [DSC], 30 ea [DSC]) [contains disodium edta, methylparaben, propylene glycol, propylparaben]

Lidocan III: 5% (1 ea, 30 ea) [contains disodium edta, methylparaben, propylene glycol, propylparaben]

Lidocanna: 4% (10 ea) [contains propyl hydroxybenzoate, propylene glycol]

Lidocore: 4% (10 ea) [contains polysorbate 80]

Lidoderm: 5% (1 ea, 30 ea) [contains disodium edta, methylparaben, propylene glycol, propylparaben]

Lidoderm: 5% (1 ea, 30 ea) [contains edetate (edta) disodium, methylparaben, propylene glycol, propylparaben]

LidoFore Flexipatch: 4% (5 ea [DSC]) [contains polysorbate 80]

Pain Relief Maximum Strength: 4% (5 ea) [contains methylparaben, polysorbate 80, propylene glycol, propylparaben]

Pharmacist Choice Pain Relief: 4% (1 ea, 5 ea, 30 ea) [fragrance free; contains polysorbate 80, propylene glycol]

Re-Lieved Maximum Strength: 4% (20 ea) [aluminum free, odor free]

Re-Lieved Maximum Strength: 4% (1 ea, 6 ea [DSC], 20 ea) [odor free]

Salonpas Pain Relieving: 4% (6 ea, 15 ea) [contains edetate (edta) disodium, methylparaben, propylene glycol, propylparaben]

Salonpas Pain Relieving: 4% (7 ea) [contains propylene glycol]

TheraCare Pain Relief: 4% (5 ea) [odor free; contains methylparaben, polysorbate 80, propylene glycol, propylparaben]

ZTlido: 1.8% (1 ea, 30 ea)

Generic: 3.5% (5 ea); 4% (10 ea, 15 ea); 5% (1 ea, 15 ea, 30 ea)

Prefilled Syringe, External, as hydrochloride:

Generic: 2% (20 mL)

Prefilled Syringe, External, as hydrochloride [preservative free]:

Glydo: 2% (6 mL, 11 mL) [pvc free]

Generic: 2% (5 mL, 10 mL)

Solution, External:

Medi-First Burn Spray: 2% (59.1 mL) [contains methylparaben, propylene glycol, propylparaben]

Solution, External, as hydrochloride:

Generic: 4% (50 mL)

Solution, Mouth/Throat, as hydrochloride:

Generic: 2% (15 mL, 100 mL)

Solution, Mouth/Throat, as hydrochloride [preservative free]:

Generic: 4% (4 mL)

Suppository, Rectal:

Generic: 50 mg (24 ea [DSC])

Generic Equivalent Available: US

May be product dependent

Pricing: US

Aerosol (Alocane Emergency Burn Max Str External)

4% (per mL): $0.13

Cream (AneCream External)

4% (per gram): $1.28

Cream (AneCream5 External)

5% (per gram): $1.60

Cream (Asperflex Lidocaine External)

4% (per gram): $0.59

Cream (Lidocaine (Anorectal) External)

5% (per gram): $0.52 - $1.97

Cream (Lidocaine External)

4% (per gram): $0.74 - $2.07

Cream (Lidocaine HCl External)

3% (per gram): $1.44 - $2.06

4% (per gram): $3.70 - $3.75

4.12% (per gram): $23.32

Cream (Lidotral External)

3.88% (per gram): $17.63

Cream (Lidotran External)

3.88% (per gram): $17.63

Cream (Lipocaine 5 External)

5% (per gram): $0.72

Cream (LMX 4 External)

4% (per gram): $1.68

Cream (LMX 5 External)

5% (per gram): $2.42

Cream (Lydexa External)

4.12% (per gram): $53.00

Cream (RectaSmoothe External)

5% (per gram): $0.64

Cream (RectiCare External)

5% (per gram): $1.23

Cream (RectoProtect External)

5% (per gram): $0.48

Gel (7T Lido External)

2% (per gram): $11.14

Gel (Alocane Emergency Burn Max Str External)

4% (per mL): $0.18

Gel (Astero External)

4% (per mL): $11.53

Gel (DermacinRx Lidogel External)

2.8% (per gram): $18.95

Gel (LDO Plus External)

4% (per mL): $13.29

Gel (LidoDose External)

3% (per mL): $3.50

Gel (LidoDose Pediatric Bulk Pack External)

3% (per mL): $3.50

Gel (Lidorex External)

2.8% (per gram): $18.95

Gel (Lubricaine External)

4% (per gram): $0.30

5% (per gram): $0.30

Gel (Proxivol External)

2% (per gram): $34.87

Gel (Sun Burnt Plus External)

4% (per mL): $0.11

Gel (Topicaine 5 External)

5% (per gram): $0.65

Gel (Topicaine External)

4% (per gram): $1.05

Gel (XeroBurn External)

2% (per gram): $0.04

Jet-injector (Zingo Intradermal)

0.5 mg (per each): $365.30

Kit (AneCream External)

4% (per each): $24.00

Kit (Lidocaine-Transparent Dressing External)

4% (per each): $59.00

Kit (LidoPure Patch External)

5% (per each): $23.44

Kit (LMX 4 Plus External)

4% (per each): $48.07

Kit (Venipuncture Px1 Phlebotomy External)

2% (per each): $981.00

Kit (Xyliderm External)

5% (per each): $3,200.00

Liquid (Dologesic Pain Relief Roll-On External)

4% (per mL): $0.13

Lotion (Lido-Sorb External)

3% (per mL): $13.87

Lotion (Lidocaine HCl External)

3% (per mL): $14.10

Ointment (Asperflex Lidocaine External)

4% (per gram): $0.07

Ointment (Lidocaine External)

4% (per gram): $6.00

5% (per gram): $7.50 - $13.00

Pads (Alocane Emergency Burn Max Str External)

4% (per each): $1.31

Patch (Asperflex Pain Relieving External)

4% (per each): $1.22

Patch (First Care Pain Relief External)

4% (per each): $46.00

Patch (Lido King External)

4% (per each): $1.18

Patch (Lidocaine External)

3.5% (per each): $46.20

4% (per each): $46.00 - $49.50

5% (per each): $3.42 - $49.80

Patch (Lidocan External)

5% (per each): $64.17

Patch (Lidocan III External)

5% (per each): $33.17

Patch (Lidoderm External)

5% (per each): $31.81

Patch (Pharmacist Choice Pain Relief External)

4% (per each): $1.50

Patch (Re-Lieved Maximum Strength External)

4% (per each): $4.79

Patch (Salonpas Pain Relieving External)

4% (per each): $1.35

Patch (ZTlido External)

1.8% (per each): $14.16

Prefilled Syringe (Glydo External)

2% (per mL): $1.19

Prefilled Syringe (Lidocaine HCl Urethral/Mucosal External)

2% (per mL): $1.38 - $1.44

Solution (Lidocaine HCl External)

4% (per mL): $0.64 - $1.33

Solution (Lidocaine HCl Mouth/Throat)

4% (per mL): $8.24

Solution (Lidocaine Viscous HCl Mouth/Throat)

2% (per mL): $0.13 - $1.18

Solution (Medi-First Burn Spray External)

2% (per mL): $0.05

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Gel, External, as hydrochloride:

Xylocaine: 2% (30 mL) [contains methylparaben, propylparaben]

Ointment, External:

Lidodan: 5% (15 g, 30 g, 35 g)

Xylocaine: 5% (35 g) [contains polyethylene glycol (macrogol), propylene glycol]

Prefilled Syringe, External, as hydrochloride:

Jelido: 2% (6 mL, 11 mL)

Xylocaine: 2% (10 mL)

Generic: 2% (1 ea)

Solution, Intratracheal, as hydrochloride:

Xylocaine Spray: 10 mg/actuation (50 mL) [contains alcohol, usp, menthol, polyethylene glycol (macrogol), saccharin]

Generic: 10 mcg/actuation (30 mL, 60 mL)

Administration: Adult

Topical:

Cream, gel, lotion: For external use only; avoid contact with eyes. Also refer to manufacturer's labeling for additional product-specific application instructions.

Intradermal injection: Refer to manufacturer's labeling for administration technique. Apply intradermal lidocaine 1 to 3 minutes prior to needle insertion; perform procedure within 10 minutes following application. Application of one additional intradermal lidocaine at a new location is acceptable after a failed attempt at venous access; multiple administrations of intradermal lidocaine at the same location are not recommended. Only use on intact skin and on skin locations where an adequate seal can be maintained. Do not use on body orifices, mucous membranes, around the eyes, or on areas with a compromised skin barrier. When removing the device from the pouch, be careful not to touch the purple outlet (open end) to avoid contamination; do not use if the device has been dropped or if the pouch is damaged or torn.

Jelly:

Urethral anesthesia: Anesthesia occurs within several minutes (full anesthetic effect occurs in 5 to 10 minutes after installation).

Lubricant for endotracheal intubation (Glydo): Avoid introducing jelly into lumen of the tube. Do not use to lubricate endotracheal stylets. Avoid use of endotracheal tubes with dried jelly on the external surface for lack of lubricating effect.

Ointment: Use of a sterile gauze is suggested for application to broken skin; apply to tube prior to intubation. In dentistry, apply to previously dried oral mucosa; subsequent removal of excess saliva with cotton rolls or saliva ejector minimizes dilution of ointment, permits maximum penetration, and minimizes possibility of swallowing the ointment. For use with the insertion of new dentures, apply to all denture surfaces contacting mucosa. Also refer to manufacturer's labeling for additional product-specific application instructions.

Oral topical solution (2% viscous):

Mouth irritation or inflammation: Have patient swish medication around mouth and then spit it out. Do not eat or chew gum for 60 minutes following use.

Pharyngeal anesthesia: Patient should gargle and may swallow medication. Do not eat or chew gum for 60 minutes following use.

Oral topical endotracheal solution, metered-dose spray (10 mg/actuation) [Canadian product]: Attach nozzle and prime pump 5 to 10 times prior to first use; prime ~2 times (to remove air) when switching to a new nozzle. Product should be in upright position while spraying. Do not modify manufacturer supplied nozzle. Discard nozzle after use (do not reuse). Do not use on cuffs or endotracheal tubes made of plastic (may damage cuff).

Patch: Note: In general, the following instructions are considered applicable to all transdermal products; also refer to manufacturer's labeling for additional product-specific application instructions.

Apply to most painful area of skin immediately after removal from protective envelope. Do not apply to nonintact skin. Some products may be cut to appropriate size (refer to manufacturer's labeling for details). Clothing may be worn over application area. Remove immediately if irritation or a burning sensation occurs. Wash hands after application. Contact with water (eg, bathing, swimming, showering) recommendations vary by product; refer to manufacturer's labeling for details. Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub). After removal from skin, fold used patch so the adhesive side sticks to itself and dispose of in trash away from children and pets.

Spray: For external use only; avoid contact with eyes. Avoid large quantities of spray, particularly on raw or blistered areas. Shake well. When applying to the face, spray on palm or hand first, then gently apply to face.

Rectal:

Rectal suppository: Remove wrapper; insert suppository into the rectum.

Administration: Pediatric

Topical:

Cream, gel: Apply to affected area.

LMX-4: Minor dermal procedure (peripheral IV cannulation, venipuncture): Infants and Children: Apply to skin at least 30 minutes before procedure; in most trials, occlusion of the application site was used (Ref) while another trial showed that occlusion was not required (Ref); however, occlusion of the site may be helpful in active infants and children to hold cream in place

Intradermal injection device (eg, Zingo): Refer to manufacturer's labeling for administration technique. Apply intradermal lidocaine 1 to 3 minutes prior to needle insertion; perform procedure within 10 minutes following application. Application of one additional intradermal lidocaine at a new location is acceptable after a failed attempt at peripheral IV cannulation; multiple administrations of intradermal lidocaine at the same location are not recommended. Only use on intact skin and on skin locations where an adequate seal can be maintained. Do not use on body orifices, mucous membranes, around the eyes, or on areas with a compromised skin barrier. When removing the device from the pouch, be careful not to touch the purple outlet (open end) to avoid contamination; do not use if the device has been dropped or the pouch is damaged or torn.

Ointment: Use of a sterile gauze is suggested for application to broken skin; apply to tube prior to intubation. In dentistry, apply to previously dried oral mucosa; subsequent removal of excess saliva with cotton rolls or saliva ejector minimizes dilution of ointment, permits maximum penetration, and minimizes possibility of swallowing the ointment. For use with the insertion of new dentures, apply to all denture surfaces contacting mucosa.

Oral solution (2% viscous): Do not eat or chew gum for 60 minutes following use.

Mouth irritation or inflammation: Have patient swish medication around mouth and then spit it out. In children <3 years, apply small amount to affected area with cotton-tipped applicator (do not use to relieve teething pain).

Pharyngeal anesthesia: Patient should gargle and may swallow medication. In children <3 years, apply to affected area with cotton-tipped applicator.

Rectal gel: Children ≥12 years and Adolescents: If possible, clean affected area with mild soap and water and blot dry prior to application.

Topical patch:

OTC 4%: Children ≥12 years and Adolescents: Remove protective film and apply to painful area. Avoid contact with eyes or mucous membranes. Wash hands after application. Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub). Discard any used or unused patches by folding adhesive sides together and dispose of in trash away from children and pets.

Topical oral endotracheal solution, metered-dose spray (10 mg/actuation) [Canadian product]: Attach nozzle and prime pump by actuating 5 to 10 times prior to first use; actuate ~2 times (to remove air) when switching to a new nozzle. Product should be in upright position while spraying. Do not modify manufacturer supplied nozzle. Discard nozzle after use (do not reuse). Do not use on cuffs or endotracheal tubes made of plastic (may damage cuff).

Use: Labeled Indications

Intradermal injection (Zingo): Topical local analgesia prior to venipuncture or peripheral IV cannulation in children ≥3 years of age; topical local analgesia prior to venipuncture in adults.

Jelly: Prevention and control of pain in procedures involving the male and female urethra; for topical treatment of painful urethritis; lubricant for endotracheal intubation (oral, nasal) (Glydo only).

Oral topical solution (2% viscous): Topical anesthesia of irritated or inflamed oral mucous membranes and pharyngeal tissue; reducing gagging during the taking of x-ray. Note: Not approved for relief of teething pain and discomfort in infants and children; serious adverse (toxic) effects have been reported (AAP 2011; AAPD 2012; ISMP 2014).

Oral topical solution (4%): Topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract. Note: Not approved for relief of teething pain and discomfort in infants and children; serious adverse (toxic) effects have been reported (AAP 2011; AAPD 2012; ISMP 2014).

Oral topical solution (metered-dose spray) [Canadian product]: Topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract.

Patch:

1.8% (ZTlido): Relief of pain associated with postherpetic neuralgia.

3.5% products: Temporary relief of minor localized pain.

4% products: Temporary relief of minor localized pain.

5% products: Relief of pain associated with postherpetic neuralgia.

Rectal: Temporary relief of pain and itching due to anorectal disorders.

Topical: Local anesthetic for mucous membrane of the oropharynx; lubricant for intubation; use in laser/cosmetic surgeries; pruritus, pruritic eczemas, insect bites, pain, soreness, minor burns (including sunburns), cuts, and abrasions of the skin; discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes; local management of skin wounds, including pressure ulcers, venous stasis ulcers, first- and second-degree burns, and superficial wounds and scrapes. Indications may vary by product; also refer to manufacturer’s labeling.

Medication Safety Issues
Pediatric patients: High-risk medication:

KIDs List: Lidocaine viscous oral solution, when used in pediatric patients <2 years of age for teething, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be avoided due to risk of seizures, arrhythmia, and death (from CNS depression, seizures, and dysrhythmias) (strong recommendation; high quality of evidence) (PPA [Meyers 2020]).

Metabolism/Transport Effects

Substrate of CYP1A2 (minor), CYP2A6 (minor), CYP2B6 (minor), CYP2C9 (minor), CYP3A4 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Antiarrhythmic Agents (Class IB): Lidocaine (Topical) may enhance the adverse/toxic effect of Antiarrhythmic Agents (Class IB). Risk C: Monitor therapy

Cimetidine: May increase the serum concentration of Lidocaine (Topical). Risk C: Monitor therapy

Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Risk C: Monitor therapy

Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor therapy

Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor therapy

Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor therapy

Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid lidocaine/prilocaine in infants receiving such agents. Risk C: Monitor therapy

Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor therapy

Pregnancy Considerations

Lidocaine and its metabolites cross the placenta and can be detected in the fetal circulation following injection (Cavalli 2004; Mitani 1987). The amount of lidocaine absorbed topically (and therefore available systemically to potentially reach the fetus) varies by dose administered, duration of exposure, and site of application. Cumulative exposure from all routes of administration should be considered.

Breastfeeding Considerations

Information regarding the presence of lidocaine in breast milk following topical administration has not been located. Lidocaine is present in breast milk following systemic administration (Dryden 2000; Giuliani 2001; Lebedevs 1993; Ortega 1999; Zeisler 1986). However, the oral bioavailability is low and rapid biotransformation occurs via the liver. The amount of lidocaine to reach the bloodstream of a breastfed infant is expected to be low and would be unlikely to cause adverse effects (Dryden 2000; Giuliani 2001; Lebedevs 1993; Ortega 1999).

Lidocaine is considered compatible with breastfeeding (WHO 2002). The manufacturer recommends caution be used when administering topical lidocaine to breastfeeding women. Cumulative exposure from all routes of administration should be considered.

Monitoring Parameters

Monitor patients for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue).

Mechanism of Action

Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction

Pharmacokinetics (Adult Data Unless Noted)

Onset: Intradermal injection: 1 to 3 minutes; Topical: 3 to 5 minutes; Transdermal: ~4 hours (Davies 2004)

Duration: Intradermal injection: 10 minutes

Absorption: Transdermal (5%): 3% ± 2% (following application of 3 patches), extent and rate variable; dependent upon concentration, dose, application site, and duration of exposure

Protein binding: 60% to 80%

Metabolism: Hepatic via CYP1A2 (major) and CYP3A4 (minor); active metabolites monoethylglycinexylidide (MEGX) and glycinexylidide (GX)

Half-life, elimination: IV: 1.5 to 2 hours; prolonged 2-fold or more in hepatic impairment

Time to peak: Transdermal (5%): 11 hours (following application of 3 patches); Transdermal (1.8%): ~14 hours (following application of 3 patches)

Excretion: Urine (<10% as unchanged drug)

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: Accumulation of metabolites may occur.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Lido | Lidocaine | Procomil | Rialocaine | Versatis | Xylocaine | Xylophil | Zalocain;
  • (AR) Argentina: Fullcaina | Gobbicaina | Indican | Lidocaina | Lidocaina Denver Farma | Lidocaina lafedar | Lidoxa | Lignocaina | Lmx | Regiocaina | Xylocaina;
  • (AT) Austria: Dynexan | Lidbree | Posterisan akut | Versatis | Xylocain;
  • (AU) Australia: Amcal skinsolve | Lignocaine | Lignocaine hydrochloride | Lmx4 | Montavit Cathejell Lignocaine | Mucosoothe | Nervoderm | Stud 100 | Versatis | Xylocaine | Xylocaine c chlor | Xylocaine c hibit | Ziagel;
  • (BD) Bangladesh: Jasocaine | Leecaine | Lido | Xylogel | Xyloken | Z lidocaine;
  • (BE) Belgium: Lonqtiv | Ophtesic | Severtos | Versatis | Xylocaine;
  • (BF) Burkina Faso: Procomil;
  • (BG) Bulgaria: Lidbree | Lidocain | Versatis;
  • (BR) Brazil: Cloridrato de lidocaina | Dermomax | Gel-lido | Labcaina | Lidial | Lido | Lidocaina | Lidogel | Lidojet | Lidol | Lidopass | Toperma | Xylestesin | Xylocaina;
  • (CH) Switzerland: Neurodol | Solarcaine | Xylocain;
  • (CL) Chile: Dimecaina | Exido | Gelcain | Lidocaina | Prolong;
  • (CN) China: Lidocaine | Lidocaine hydrochloride mucilage (i) | Xylocaine;
  • (CO) Colombia: Farmacaina | Lidocaina | Lidocaina Hcl | Lidomax | Roxicaina | Versatis | Xylocaina;
  • (CZ) Czech Republic: Lidbree | Lidocain | Versatis | Xylestesin | Xylocaine;
  • (DE) Germany: Actilogic | Burn jel | Calmotop | Dolocupin | Dynexan | Esliva | Gelicain | Lidesthesin | Lido Posterine | Lidocain | Lidocainkreussler | Lidogalen | Lidoposterine | Lidotec | Lonioban | Posterisan akut | Sagittaproct gleitgel lidocain | Versatis | Xylocain | Xylocain pumpspray dental | Xylonor n;
  • (DK) Denmark: Xogel | Xylocain;
  • (DO) Dominican Republic: Lafecaina | Lidocaina | Roxicaina | Xylestesin | Xylocaina;
  • (EC) Ecuador: Roxicaina | Versatis | Xylocaina;
  • (EE) Estonia: Lidocain | Lidonostrum | Lignocaine | Vemcaine | Versatis | Xylocaine | Xylonor;
  • (EG) Egypt: Dento-gel | Farco-caine | Lidocaine | Lidoged | Lidosine | Lignocaine | Lignoral | Proctolidosine | Ultracaine | Xylocaine | Xylotop;
  • (ES) Spain: Aeroderm | Dermovagisil | Lambdalina | Lidbree | Ophtesic | Versatis | Xilonibsa | Xylocaina;
  • (ET) Ethiopia: Lidocaine;
  • (FI) Finland: Lidbree | Lidocain | Lidoposterin | Xylocain;
  • (FR) France: Dynexan | Dynexangival | Lidocaine Aguettant | Ophtesic | Versatis | Xylocaine;
  • (GB) United Kingdom: Boots Anaesthetic Sore Throat Relief | Dequa | Lidbree | Lidocaine | Lignocaine | Lignocaine biorex | Lmx4 | Premjact | Ralvo | Strepsils | Strepsils pain relief | Stud 100 | Versatis | Xylocaine | Xylonar;
  • (GR) Greece: Versatis | Xylocaine | Xylojell | Xylozan;
  • (HK) Hong Kong: Axcel lignocaine | Lignocaine | Lignocaine hydrochloride | Lignopad | Magicmo | Procomil | Xylocaine;
  • (HR) Croatia: Dolokain | Lidokain | Versatis;
  • (HU) Hungary: Lidbree | Lidocain | Versatis;
  • (ID) Indonesia: Lidonest | Xylocain | Xylocaine;
  • (IE) Ireland: Burnjel | Lidbree | Versatis;
  • (IL) Israel: After burn | Esracain | Lidocain | Xylocaine;
  • (IN) India: Caligno | Climax | Easycainne | Exygra | Gesicain | Lidfast | Lidopatch | Lidovalor | Lignocad | Lignocare | Lignox | Lox | Nummit | Oculan | Orikane | Resocaine | Stud | Wocaine | Xylocaine | Xynova | Zylo;
  • (IQ) Iraq: Awalidocaine | Licodain | Lido rx | Lidocain | Lidocan k | Xylocaine;
  • (IT) Italy: Dolocopin | Dynexan | Ecocain | Elidoxil | Lidoc | Lidocaina | Lidocaina aguettant | Lidocaina formenti | Lidofast | Luan | Nydriar | Ortodermina | Truvinut | Versatis | Xilomynol | Xylocaina;
  • (JO) Jordan: Lidover | Xylocaine | Xylophil;
  • (JP) Japan: Anetocaine | Anetocaine kobayashi kako | Anetocaine merck hoei | Lidocaine | Partran | Penles | Xylocaine | Youpatch;
  • (KE) Kenya: Metacain | Xylocaine;
  • (KR) Korea, Republic of: Acaine | Anestar | Angelcain | Anyman | Anymen | Arlico lidocaine hcl | B.m.gel | Beracaine | Beros | Bigtugel | Bluecain | Burncain | Burnen | Caeplong | Camna | Caplong | Cmg primium | Control | Cresen | Dermacan | Dipenlong | Dube | Emmao Plus | Engelcaine | Engelcaine jelly | Erex | Happycain | Hecaine | J | J cain premium | J-cain | J-ker | Jw shinyak lidocaine | Keflong | Korea pharma lidocaine | Lica l | Lidcaine | Lido m | Lidoa f | Lidoca | Lidocain jelly sungkwang | Lidocaine | Lidocan | Lidogesic cataplasma | Lidokin | Lidoplast | Liocaine f | Liocan | Lipo-max | Lmx4 | Maxcaine | Power | Powergel | Premium lido sen | Primium tag | Progelcaine | Ps | Rejucell | Riocan | Rocky gel | Rokygel | S caine | S.m.gel | Sanoba | Sc | Seracaine | Skincain | Stud | T-stone | Testokin | Thecaine | Veracaine | Wellscain | Xilonibsa | Xogel adult | Xylocaine | Yucaine | Zk ina;
  • (KW) Kuwait: Rialocaine | Versatis | Xylocaine | Zalocain;
  • (LB) Lebanon: Avocaine | Lidocain | Lmx | Versatis | Xylocaine;
  • (LT) Lithuania: Akten | Lidocain | Lidocain egis | Lidoposterin | Versatis | Xylocaine;
  • (LU) Luxembourg: Dynexan | Ophtesic | Severtos | Xylocaine;
  • (LV) Latvia: Lidocain | Versatis | Xylocaine;
  • (MA) Morocco: Lidocaine | Xylocaine;
  • (MX) Mexico: Betacaine | Hipoden | Lambdalina | Lidocaina | Pharmacaine | Pisacaina | Rucaina | Sensipharma | Sunicaine | Undorlan | Versatis | Xylocaina | Xylocaina d | Xylocaina m | Zk ina;
  • (MY) Malaysia: Axcel lignocaine | Gesicain | Lidocaine | Lignocaine | Lignopad | Lignoral | Locanest | Lox | Metacain | Xylocaine;
  • (NG) Nigeria: Lidocaine;
  • (NL) Netherlands: Dynexan | Instillido | Lidbree | Lidocaine vaselinecreme 3% FNA | Versatis | Xylocaine;
  • (NO) Norway: Acoin lidocainhydrochlorid orifarm | Posterisan akut | Versatis | Xylocain | Xylocaine;
  • (NZ) New Zealand: Cathejell lignocaine | Instillagel lido | Lignocaine | Lignocaine HCL | Lmx4 | Mucosoothe | Versatis | Xylocaine plain;
  • (PE) Peru: Cirocaina | Lidocaina | Lidopharm | Prolong | Roxicaina | Versatis | Xilonest | Xylocaina;
  • (PH) Philippines: Lidocaine HCL | Lignopad | Xylocaine;
  • (PK) Pakistan: Arocaine | Donligno | Lignocaine | Lignodine | Lignopharm | Ruscain | Xino | Xylocaine | Xylogel | Zyocaine;
  • (PL) Poland: Dynexan | Lidocain | Lidocain egis | Lidoderm | Lidogel | Lidoposterin | Lignocainum hydrochloricum | Lignox | Nanolipo | Versatis | Xylocain | Xylocaine;
  • (PR) Puerto Rico: Alocane | Alocane emergency burn pads | Anecream 5 | Aspercreme with lidocaine | Asperflex | Astero | Bengay tropical jasmine | Blue emu numbing pain relief | Blue tube | Burn jel | Burn Jel Plus | Burnstuff | Cidaleaze | Dermalid | Eha | Firstcare pain relief | Gen7t | Glydo | Healthwise pain relief | L.m.x. 4 plus | Lc 4 | Lc 5 | Ldo plus | Lidaflex | Lidamantle | Lido king | Lido sorb | Lidocaine | Lidocaine anorectal | Lidocaine HCL | Lidocaine Hydrochloride Jelly | Lidocanna | Lidocin | Lidocream | Lidoderm | Lidodose | Lidogel | Lidoheal 90 | Lidopac | Lidopure | Lidoreal 30 | Lidorex | Lidorxkit | Lidosense | Lidotral | Lidotrans | Lidovix l | Lidozion | Lipocaine | Lmx | Lubricaine | Lydexa | Miaderm l | Re lieved | Rectasmoothe | Recticare | Salonpas lidocaine | Sun basics burn relief | Topicaine | Tranzarel | Xylocaine | Ziloval | Zionodil | Ztlido;
  • (PT) Portugal: Lambdalina | Lidbree | Lidocaina | Lidocaina grunenthal | Lidoject | Lidonostrum | Versatis | Vessatis | Xilonibsa | Xilotane | Xylocaina;
  • (PY) Paraguay: Curadentol | Indican | Procomil | Regiocaina | Xylestesin | Xylocaina;
  • (QA) Qatar: Avocaine | Ledo | Lidonostrum | Lokalen | Rialocaine | Rialocaine Gel | Themicaine | Vemcaine | Versatis | Xylocaine Jelly | Xylocaine Spray | Xylocaine Topical | Zalocain;
  • (RO) Romania: Lidbree | Lidocain | Versatis;
  • (RU) Russian Federation: Catedejel lidocain | Dinexan | Dinexan a | Dynexan | Lidocain | Lidocain vial | Lidocaine vial | Lidochlor | Luan | Versatis | Xylocaine;
  • (SA) Saudi Arabia: Ledo | Lidocaine | Liocaine | Rialocaine | Versatis | Xylocaine | Xylocaine viscous | Xylophil | Zalocain;
  • (SE) Sweden: Instillido | Lidbree | Maxilene | Versatis | Xylocain | Xylocain utan konserveringsmedel;
  • (SG) Singapore: Dube | Gesicain | Lignocaine | Lignopad | Vagisil medicated cream | Xylocaine;
  • (SI) Slovenia: Cathejell lidokain | Lidocain | Versatis | Xylocain | Xylonor;
  • (SK) Slovakia: Lidbree | Lidocain | Versatis | Xylocaine;
  • (TH) Thailand: Chalocaine | Docaine | Lido | Lignopad | Xylocaine;
  • (TN) Tunisia: Lidoca plus | Xylocaine | Xylocaine Uretral | Xylogel;
  • (TR) Turkey: Anestol | Joymax | Ksilidin | Lidestol | Lincaine | Lmx 4 | Localen | Locanest | Lokalen | Precoxin | Redekain | Vemcaine | Xylocain;
  • (TW) Taiwan: Anebol | Donku | Lico | Lido | Lidopat | Lignocaine | Lignopad | Medisuper | Quicaine | Xylocaine;
  • (UA) Ukraine: Lidocain | Luan;
  • (UG) Uganda: Axcel lignocaine;
  • (UY) Uruguay: Lidocaina | Lignocaina | Xylo Efa | Xylocaina;
  • (VE) Venezuela, Bolivarian Republic of: Farmacaina | Lidocaina | Nenedent | Toperma | Xilocaina;
  • (ZA) South Africa: Remicaine | Versatis | Xylocaine | Xylotox;
  • (ZM) Zambia: Xcite;
  • (ZW) Zimbabwe: Metacain
  1. 7T Lido (lidocaine) gel [prescribing information]. Los Angeles, CA: 7T Pharma LLC; October 2018.
  2. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  3. Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597. [PubMed 3960626]
  4. Alocane Emergency Burn Spray Maximum Strength (lidocaine) gel [prescribing information]. Pleasant Prairie, WI: Quest Products Inc; received September 2020.
  5. American Academy of Pediatric Dentistry (AAPD). Guideline on infant oral health care. 2012. http://www.aapd.org/media/Policies_Guidelines/G_infantOralHealthCare.pdf.
  6. American Academy of Pediatrics Oral Health Initiative (AAP). A Pediatric Guide to Children’s Oral Health. January, 2011. http://www2.aap.org/commpeds/dochs/oralhealth/docs/OralHealthFCpagesF2_2_1.pdf.
  7. American Academy of Pediatrics Task Force on Circumcision. Male circumcision. Pediatrics. 2012;130:e756.
  8. Anastia (lidocaine) [prescribing information]. Peoria, AZ: Solutech Pharmaceuticals LLC.; received September 2016.
  9. Antel R, Ingelmo P. Local anesthetic systemic toxicity. CMAJ. 2022;194(37):E1288. doi:10.1503/cmaj.220835 [PubMed 36162843]
  10. Aspercreme (lidocaine) patch [prescribing information]. Chattanooga, TN: Chattam Inc; received March 2018.
  11. Aspercreme with Lidocaine Foot Pain Creme (lidocaine) [prescribing information]. Chattanooga, TN: Chattam Inc; received January 2020.
  12. Aspercreme with Lidocaine Maximum Strength Pain Relieving Creme (lidocaine) [prescribing information]. Chattanooga, TN: Chattam Inc; 2015.
  13. Asperflex Maximum Strength (lidocaine) [prescribing information]. Fairfield, NJ: Akron Pharma Inc; received July 2020.
  14. Assier H, Wolkenstein P, Chosidow O. Very late sensitization to parabens induced by repeated applications of an anaesthetic therapeutic plaster to non-damaged skin. Contact Dermatitis. 2018;79(3):194-195. doi:10.1111/cod.13029 [PubMed 29790180]
  15. Astero (lidocaine) gel [prescribing information]. Miami, FL: Gensco Laboratories LLC; June 2019.
  16. Bacon B, Silverton N, Katz M, et al. Local anesthetic systemic toxicity induced cardiac arrest after topicalization for transesophageal echocardiography and subsequent treatment with extracorporeal cardiopulmonary resuscitation. J Cardiothorac Vasc Anesth. 2019;33(1):162-165. doi:10.1053/j.jvca.2018.01.044 [PubMed 29525187]
  17. Becker DE, Reed KL. Essentials of local anesthetic pharmacology. Anesth Prog. 2006;53(3):98-108; quiz 109-110. doi:10.2344/0003-3006(2006)53[98:EOLAP]2.0.CO;2 [PubMed 17175824]
  18. Becker DE, Reed KL. Local anesthetics: review of pharmacological considerations. Anesth Prog. 2012;59(2):90-101; quiz 102-103. doi:10.2344/0003-3006-59.2.90 [PubMed 22822998]
  19. Blue Tube (lidocaine) cream [prescribing information]. Knoxville, TN: Focus Health Group; received June 2020.
  20. Brites GS, Ferreira I, Sebastião AI, et al. Allergic contact dermatitis: From pathophysiology to development of new preventive strategies. Pharmacol Res. 2020;162:105282. doi:10.1016/j.phrs.2020.105282 [PubMed 33161140]
  21. Cavalli Rde C, Lanchote VL, Duarte G, et al. Pharmacokinetics and Transplacental Transfer of Lidocaine and its Metabolite For Perineal Analgesic Assistance to Pregnant Women. Eur J Clin Pharmacol. 2004;60(8):569-574. [PubMed 15365654]
  22. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  23. Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199. http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm. [PubMed 6423951]
  24. Curtis LA, Dolan TS, Seibert HE. Are one or two dangerous? Lidocaine and topical anesthetic exposures in children. J Emerg Med. 2009;37(1):32-39. doi:10.1016/j.jemermed.2007.11.005 [PubMed 18280086]
  25. Davies PS and Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs. 2004;64(9):937-947. [PubMed 15101784]
  26. Dologesic (lidocaine) [prescribing information]. Miami, FL: Llorens Pharmaceutical International Division, Inc.; February 2018.
  27. Dryden RM, Lo MW. Breast milk lidocaine levels in tumescent liposuction. Plast Reconstr Surg. 2000;105(6):2267-2268. [PubMed 10839430]
  28. Dykewicz MS, Lam JK. Drug hypersensitivity reactions. Med Clin North Am. 2020;104(1):109-128. doi:10.1016/j.mcna.2019.09.003 [PubMed 31757230]
  29. Eha lotion (lidocaine) [prescribing information]. Torrance, CA: Enovachem Pharmaceuticals; received September 2016.
  30. Eichenfield LF, Funk A, Fallon-Friedlander S, Cunningham BB. A clinical study to evaluate the efficacy of ELA-Max (4% liposomal lidocaine) as compared with eutectic mixture of local anesthetics cream for pain reduction of venipuncture in children. Pediatrics. 2002;109(6):1093-1099. [PubMed 12042548]
  31. Eisenberg J, Tedford NJ, Weaver N, Becker S, Moss MJ. Adverse outcomes in topical lidocaine exposure: A pediatric case series from the United States National Poison Data System. Clin Pediatr (Phila). 2023;62(11):1390-1397. doi:10.1177/00099228231159646 [PubMed 36908108]
  32. Fein JA, Zempsky WT, Cravero JP; Committee on Pediatric Emergency Medicine and Section on Anesthesiology and Pain Medicine; American Academy of Pediatrics. Relief of pain and anxiety in pediatric patients in emergency medical systems. Pediatrics. 2012;130(5):e1391-e1405. [PubMed 23109683]
  33. Gay HC, Amaral AP. Acquired methemoglobinemia associated with topical lidocaine administration: A Case Report. Drug Saf Case Rep. 2018;5(1):15. doi:10.1007/s40800-018-0081-4 [PubMed 29627919]
  34. Gen7T (lidocaine) lotion [prescribing information]. Las Vegas, NV: 7T Pharma LLC; received September 2019.
  35. Gen7T (lidocaine) patch [prescribing information]. Las Vegas, NV: 7T Pharma LLC; received September 2019.
  36. Giard MJ, Uden DL, Whitlock DJ, and Watson DM. Seizures induced by oral viscous lidocaine. Clin Pharm. 1983;2(2):110. [PubMed 6883940]
  37. Gitman M, Fettiplace MR, Weinberg GL, Neal JM, Barrington MJ. Local anesthetic systemic toxicity: A narrative literature review and clinical update on prevention, diagnosis, and management. Plast Reconstr Surg. 2019;144(3):783-795. doi:10.1097/PRS.0000000000005989 [PubMed 31461049]
  38. Giuliani M, Grossi GB, Pileri M, Lajolo C, Casparrini G. Could local anesthesia while breast-feeding be harmful to infants? J Pediatr Gastroenterol Nutr. 2001;32(2):142-144. [PubMed 11321382]
  39. Glydo (lidocaine) jelly, USP [prescribing information]. Schaumberg, IL: Sagent Pharmaceuticals; March 2020.
  40. Gonzalez del Rey J, Wason S, Druckenbrod RW. Lidocaine overdose: another preventable case? Pediatr Emerg Care. 1994;10(6):344-346. [PubMed 7899121]
  41. Hardwick N, King CM. Contact allergy to lignocaine with cross-reaction to bupivacaine. Contact Dermatitis. 1994;30(4):245-246. doi:10.1111/j.1600-0536.1994.tb00657.x [PubMed 8033557]
  42. Hasan B, Asif T, Hasan M. Lidocaine-induced systemic toxicity: A case report and review of literature. Cureus. 2017;9(5):e1275. doi:10.7759/cureus.1275. Erratum in: Cureus. 2019;11(8):c24 [PubMed 28652958]
  43. Hess GP and Walson PD. Seizures secondary to oral viscous lidocaine. Ann Emerg Med. 1988;17(7):725-727. [PubMed 3382075]
  44. Hotta E, Tamagawa-Mineoka R, Onishi Y, et al. Immediate hypersensitivity reaction to carboxymethylcellulose in lidocaine jelly and dimethicone drops: A case report and mini-review. J Cutan Immunol Allergy. 2022;5:217-221. doi:12.1002/cia2.12261
  45. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  46. Institute for Safe Medication Practice (ISMP), “Topical anesthetics for teething infants,” ISMP Medication Safety Alert, January 14, 2014. http://www.ismp.org/newsletters/acutecare/issues/20140116.pdf.
  47. Iolascon A, Bianchi P, Andolfo I, et al; SWG of red cell and iron of EHA and EuroBloodNet. Recommendations for diagnosis and treatment of methemoglobinemia. Am J Hematol. 2021;96(12):1666-1678. doi:10.1002/ajh.26340 [PubMed 34467556]
  48. Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47(5):312-313. [PubMed 12534540]
  49. Koh JL, Harrison D, Myers R, Dembinski R, Turner H, McGraw T. A randomized, double-blind comparison study of EMAL and ELA-Max for topical anesthesia in children undergoing intravenous insertion. Paediatr Anesth. 2004;14(12):977-982. [PubMed 15601345]
  50. LDO Plus (lidocaine) gel [prescribing information]. Miami, FL: Gensco Laboratories LLC; October 2015.
  51. Lebedevs TH, Wojnar-Horton RE, Yapp P, et al. Excretion of Lignocaine and its Metabolite Monoethylglycinexylidide in Breast Milk Following its Use in a Dental Procedure. A Case Report. J Clin Periodontol. 1993;20(8):606-608. [PubMed 8408724]
  52. Lehr VT, Cepeda E, Frattarelli DA, et al, "Lidocaine 4% Cream Compared With Lidocaine 2.5% and Prilocaine 2.5% or Dorsal Penile Block for Circumcision," Am J Perinatol, 2005, 22(5):231-7. [PubMed 16041631]
  53. LidaFlex (lidocaine) [prescribing information]. Baton Rouge, LA: Sola Pharmaceuticals LLC; received February 2021.
  54. Lidocaine 3.5% patch [prescribing information]. Las Vegas, NV: 7T Pharma, LLC; received August 2023.
  55. Lidocaine 5% ointment [prescribing information]. Amityville, NY: Hi-Tech Pharmacal Co Inc; February 2020.
  56. Lidocaine 4% ointment [prescribing information]. Hauppauge, NY: AUM Pharmaceuticals; received February 2021.
  57. Lidocaine hydrochloride 3% lotion [prescribing information]. Ocean Springs, MS: Alvix Laboratories; February 2015.
  58. Lidocaine hydrochloride 4.12% cream [prescribing information]. San Fernando, CA: PharmaPure RX; April 2017.
  59. Lidocaine hydrochloride gel [prescribing information]. Holland, OH: Quality Care Products, LLC; December 2016.
  60. Lidocaine hydrochloride solution [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp; August 2016.
  61. Lidocaine hydrochloride topical solution [prescribing information]. Buena, NJ: Teligent Pharma Inc; February 2020.
  62. Lidocaine suppository (lidocaine) [prescribing information]. Hot Springs, AR: Burke Therapies LLC; January 2021.
  63. Lidocaine Viscous 2% (lidocaine) [prescribing information]. Carmel, NY: Lannett Company, Inc; February 2021.
  64. Lidocan Patch 5% (lidocaine) [prescribing information]. Panorama City, CA; PureTek Corp; received July 2023.
  65. Lidoderm (lidocaine patch 5%) [prescribing information]. Malvern, PA: Endo Pharmaceuticals; November 2018.
  66. LidoDose (lidocaine hydrochloride 3%) topical anesthetic, single-use applicator [prescribing information]. Miami, FL: Gensco Pharma; April 2019.
  67. Lido-K (lidocaine) [prescribing information]. Peoria, AZ: Solutech Pharmaceuticals; February 2018.
  68. Lidopatch (lidocaine) [prescribing information]. Lake Forest, IL: JAR Laboratories; November 2017.
  69. LiDORx (lidocaine) gel [prescribing information]. Miami, FL: Gensco Pharma LLC; November 2018.
  70. Lido-Rx 4.1 (lidocaine) [prescribing information]. Pensacola, FL: Cloverleaf Pharma LLC; January 2016.
  71. Lidotran (lidocaine cream 3.88%) [prescribing information]. Panorama City, CA: PureTek Corporation; March 2022.
  72. Lidotrex (lidocaine) gel [prescribing information]. Ripley, MS: Sterling-Knight Pharmaceuticals LLC; March 2018.
  73. Lidovex (lidocaine cream 3.75%) [prescribing information]. Ripley, MS: Sterling-Knight Pharmaceuticals; December 2014.
  74. Lidovex (lidocaine cream) [prescribing information]. Ripley, MS: Sterling-Knight Pharmaceuticals LLC; January 2015.
  75. Lipocaine 5 (lidocaine) cream [prescribing information]. Jupiter, FL: ESBA Laboratories Inc; received March 2020.
  76. LMX4 cream (lidocaine) [prescribing information]. Ferndale, MI: Ferndale Laboratories, Inc; June 2014.
  77. LMX5 cream (lidocaine) [prescribing information]. Ferndale, MI: Ferndale Laboratories, Inc; June 2014.
  78. Lodi A, Ambonati M, Coassini A, Kouhdari Z, Palvarini M, Crosti C. Contact allergy to 'caines' caused by anti-hemorrhoidal ointments. Contact Dermatitis. 1999;41(4):221-222. doi:10.1111/j.1600-0536.1999.tb06136.x [PubMed 10515104]
  79. Long B, Chavez S, Gottlieb M, Montrief T, Brady WJ. Local anesthetic systemic toxicity: A narrative review for emergency clinicians. Am J Emerg Med. 2022;59:42-48. doi:10.1016/j.ajem.2022.06.017 [PubMed 35777259]
  80. Lubricaine Anorectal (lidocaine) gel [prescribing information]. Jupiter, FL: ESBA Labs Inc; received March 2020.
  81. Lubricaine for Her (lidocaine) gel [prescribing information]. Jupiter, FL: ESBA Labs Inc; received March 2020.
  82. Luhmann J, Hurt S, Shootman M, Kennedy R. A comparison of buffered lidocaine versus ELA-Max before peripheral intravenous catheter insertions in children. Pediatrics. 2004;133(3 pt 1):e217-e220. [PubMed 14993579]
  83. Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172. [PubMed 10985636]
  84. Mackley CL, Marks JG Jr, Anderson BE. Delayed-type hypersensitivity to lidocaine. Arch Dermatol. 2003;139(3):343-346. doi:10.1001/archderm.139.3.343 [PubMed 12622627]
  85. Marra DE, Yip D, Fincher EF, Moy RL. Systemic toxicity from topically applied lidocaine in conjunction with fractional photothermolysis. Arch Dermatol. 2006;142(8):1024-1026. doi:10.1001/archderm.142.8.1024 [PubMed 16924052]
  86. Meyers RS, Thackray J, Matson KL, et al. Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List. J Pediatr Pharmacol Ther. 2020;25(3):175-191. [PubMed 32265601]
  87. Mitani GM, Steinberg I, Lien EJ, et al. The Pharmacokinetics of Antiarrhythmic Agents in Pregnancy and Lactation. Clin Pharmacokinet. 1987;12(4):253-291. [PubMed 3297463]
  88. Mofenson HC, Caraccio TR, Miller H, Greensher J. Lidocaine toxicity from topical mucosal application. With a review of the clinical pharmacology of lidocaine. Clin Pediatr (Phila). 1983;22(3):190-192. [PubMed 6825363]
  89. Montanez-Wiscovich ME, Ogbonna NJ. Geometric rash on the leg. Am Fam Physician. 2018;97(8):531-532. [PubMed 29671489]
  90. Neal JM, Barrington MJ, Fettiplace MR, et al. The Third American Society of Regional Anesthesia and Pain Medicine Practice Advisory on Local Anesthetic Systemic Toxicity: Executive Summary 2017. Reg Anesth Pain Med. 2018;43(2):113-123. doi:10.1097/AAP.0000000000000720 [PubMed 29356773]
  91. Ortega D, Viviand X, Lorec AM, et al. Excretion of Lidocaine and Bupivacaine in Breast Milk Following Epidural Anesthesia for Cesarean Delivery. Acta Anaesthesiol Scand. 1999;43(4):394-397. [PubMed 10225071]
  92. Puczynski MS, Ow EP, and Rust C. Cardiopulmonary arrest due to misuse of viscous lidocaine. Arch Otolaryngol. 1985;111(11):768-769. [PubMed 4051869]
  93. Rahimi M, Elmi M, Hassanian-Moghaddam H, et al. Acute lidocaine toxicity; a case series. Emerg (Tehran). 2018;6(1):e38. [PubMed 30009240]
  94. Rothstein P, Dornbusch J, Shaywitz BA. Prolonged seizures associated with the use of viscous lidocaine. J Pediatr. 101(3):461-463. [PubMed 7108671]
  95. Ruffles SP, Gayres JG. Fatal bronchospasm after topical lignocaine before bronchoscopy. Br Med J (Clin Res Ed). 1987;294(6588):1658-1659. doi:10.1136/bmj.294.6588.1658-a [PubMed 3113575]
  96. Sakai RI, Lattin JE. Lidocaine ingestion. Am J Dis Child. 1980;1344(3):323. [PubMed 7361745]
  97. Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009;10(2):256-259. [PubMed 19188870]
  98. Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313. [PubMed 7746084]
  99. Smith M, Wolfram W, Rose R. Toxicity- seizures in an infant caused by (or related to) oral viscous lidocaine use. J Emerg Med. 1992;10(5):587-590. [PubMed 1401862]
  100. Sobanko JF, Miller CJ, Alster TS. Topical anesthetics for dermatologic procedures: a review. Dermatol Surg. 2012;38(5):709-721. [PubMed 22243434]
  101. Solanpas (lidocaine) gel [prescribing information]. Florham Park, NJ: Hisamitsu America Inc; received May 2020.
  102. Taddio A, Soin HK, Schuh S, Koren G, Scolnik D. Liposomal lidocaine to improve procedural success rates and reduce procedural pain among children: a randomized controlled trial. CMAJ. 2005;172(13):1691-1695. [PubMed 15967972]
  103. To D, Kossintseva I, de Gannes G. Lidocaine contact allergy is becoming more prevalent. Dermatol Surg. 2014;40(12):1367-1372. doi:10.1097/DSS.0000000000000190 [PubMed 25380091]
  104. Topicaine 4 (lidocaine) gel [prescribing information]. Jupiter, FL: ESBA Laboratories Inc; January 2019.
  105. Topicaine 5 (lidocaine) gel [prescribing information]. Jupiter, FL: ESBA Laboratories Inc; received March 2020.
  106. Tramontana M, Hansel K, Bianchi L, Sensini C, Malatesta N, Stingeni L. Advancing the understanding of allergic contact dermatitis: from pathophysiology to novel therapeutic approaches. Front Med (Lausanne). 2023;10:1184289. doi:10.3389/fmed.2023.1184289 [PubMed 37283623]
  107. Tranzarel (lidocaine) [prescribing information]. Eatontown, NJ: Taleos Pharma Corp.; August 2017.
  108. Trapp L, Will J. Acquired methemoglobinemia revisited. Dent Clin North Am. 2010;54(4):665-675. doi:10.1016/j.cden.2010.06.007 [PubMed 20831930]
  109. Walters E, Wurster Ovalle V, Yin S, Dribin T. Infant with status epilepticus secondary to systemic lidocaine toxicity from topical application. BMJ Case Rep. 2020;13(1):e233119. doi:10.1136/bcr-2019-233119 Corrected and republished in: Drug Ther Bull. 2020;58(9):141-143. [PubMed 31932460]
  110. Weightman W, Turner T. Allergic contact dermatitis from lignocaine: report of 29 cases and review of the literature. Contact Dermatitis. 1998;39(5):265-266. doi:10.1111/j.1600-0536.1998.tb05928.x [PubMed 9840272]
  111. Weingarten TN, Gleich SJ, Craig JR Jr, Sprung J. Methemoglobinemia in the setting of chronic transdermal lidocaine patch use. Pain Med. 2012;13(7):976-977. doi:10.1111/j.1526-4637.2012.01383.x [PubMed 22568708]
  112. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
  113. Xylocaine 2% jelly (lidocaine hydrochloride) [prescribing information]. Lake Forest, IL: Akorn, Inc.; June 2012.
  114. Xylocaine Endotracheal (lidocaine non-aerosol spray) [package insert]. Toronto, Ontario, Canada; Aspen Pharmacare Canada Inc: March 2020.
  115. Zeisler JA, Gaarder TD, De Mesquita SA. Lidocaine excretion in breast milk. Drug Intell Clin Pharm. 1986;20(9):691-693. [PubMed 3757781]
  116. Zingo (lidocaine) [prescribing information]. Las Vegas, NV: 7T Pharma LLC; November 2018.
  117. Zionodil (lidocaine) [prescribing information]. Las Vegas, NV: Bodysphere, LLC; received December 2019.
  118. ZTlido (lidocaine) [prescribing information]. Palo Alto, CA: Scilex Pharmaceuticals Inc; April 2021.
  119. Zylotrol-L (lidocaine) [prescribing information]. Sacramento, CA: Whitestone Products LLC; received January 2022.
Topic 9478 Version 907.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟